BioAtla Investor Presentation Deck

Phase 1 CAB-CTLA-4 (BA3071) Dose Escalation Key Objectives: Define safety profile and determine Phase 2 dose and MTD Evaluate antitumor activity and immunogenicity Determine PK parameters bicatla Key Eligibility Criteria: CTLA-4 naïve Treatment refractory: melanoma non-small cell lung cancer (NSCLC) renal cell carcinoma urothelial cancer gastric cancer hepatocellular carcinoma (HCC) cervical cancer small cell lung cancer (SCLC) Combination Therapy (Q3W) Cycle 1 700 mg (~10mg/kg) 350 mg (~5mg/kg) 210 mg 70 mg 21 mg 7 mg Cycle 2+ BA3071 BA3071 +240 mg nivolumab Further dose escalation planned to 1,000 mg BioAtla| Overview 12

View entire presentation